5.2 billion IU
distributed since 1990
Unyielding dedication to safety
HUMATE-P is a made in a multi-step process that provides purity and safety every step of the way. Plasma collection, processing, and packaging procedures are designed to retain the properties of the VWF and FVIII proteins.
CSL Behring’s Integrated Safety System includes 3 steps specifically designed to identify and remove live viruses. However, the risk of viral transmission cannot be completely eliminated.
3 steps to inactivate and remove viral pathogens
HUMATE-P has a proven safety record established in 30+ years of clinical use
NO
documented viral transmission
Most common adverse reactions to HUMATE-P
In studies, more than 5% of patients reported the following adverse reactions to HUMATE-P: allergic/anaphylactic reactions, including hives, chest tightness, rash, itching, and swelling. The most common adverse reactions after surgery were bleeding at the wound or infusion site, and nosebleeds.
In 63 people who received HUMATE-P for surgery-related bleeding, the most common adverse events were postoperative bleeding (19 people, with 5 people experiencing bleeding at up to three different sites), postoperative nausea (15 people), and postoperative pain (11 people).
In 97 people who received HUMATE-P for on-demand use,4 people experienced 7 adverse events that were considered to have a possible or probable relationship to HUMATE-P. These included chills, blood vessel inflammation, blood vessel widening, abnormal sensation on the skin, itching, rash, and hives. All were mild in intensity with the exception of a moderate case of itching.
